Attivare Therapeutics Receives Grant for Malaria Vaccine
Attivare Therapeutics, a Massachusetts-based startup, has received a $6.6 million grant extension from the Gates Foundation to continue developing a vaccine for malaria. The company's technology has shown promising results in cancer clinical trials and has been extended to fight infectious diseases, including COVID-19. The project highlights the potential of collaborative research and the complex path to discovery.
Key points
- Attivare Therapeutics, a startup co-founded by Ed Doherty, has received a $6.6 million grant extension from the Gates Foundation to develop a malaria vaccine.
- The company's technology creates tiny 'factories' in the body where immune cells learn to recognize tumor cells and attack them, with promising results in cancer clinical trials.
- The project has been extended to fight infectious diseases, including COVID-19, and a COVID vaccine was created while the team was still at Harvard.
- The grant will support further development of the malaria vaccine, one of the world's deadliest infectious diseases.
Attivare Therapeutics, a Massachusetts-based startup, has made significant progress in developing a vaccine for cancer and infectious diseases. The company's technology, which creates tiny 'factories' in the body where immune cells learn to recognize tumor cells and attack them, has shown promising results in cancer clinical trials. The project has been extended to fight infectious diseases, including COVID-19, and a COVID vaccine was created while the team was still at Harvard.
The grant from the Gates Foundation will support further development of the malaria vaccine, one of the world's deadliest infectious diseases. The project highlights the potential of collaborative research and the complex path to discovery. It also underscores the importance of continued investment in vaccine development and the potential for innovation in the field.
Attivare Therapeutics was founded by Ed Doherty and his collaborators, who were working at the Wyss Institute at Harvard University. The company has received significant recognition for its work, including the grant from the Gates Foundation. The project is a testament to the power of collaborative research and the potential for innovation in the field of vaccine development.
Sources
The WireByte editorial team synthesises technology news from multiple primary sources, verifies the facts, and links every source. Articles are produced with AI assistance and reviewed under our editorial policy.